These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 38862004

  • 1. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI, Ning J, Chan RNC, Chung CT, Huang H, Ng K, Dee EC, Lee S, Kaewdech A, Chow AKM, Man NK, Liu T, Jing F, Cheung BMY, Tse G, Zhou J.
    J Natl Compr Canc Netw; 2024 Jun; 22(2 D):. PubMed ID: 38862004
    [Abstract] [Full Text] [Related]

  • 2. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes.
    Zhou J, Liu X, Chou OH, Li L, Lee S, Wong WT, Zhang Q, Chang C, Liu T, Tse G, Jing F, Cheung BMY.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1501-1510. PubMed ID: 36066415
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study.
    Chou OHI, Chauhan VK, Chung CTS, Lu L, Lee TTL, Ng ZMW, Wang KKW, Lee S, Liu H, Pang RTK, Kaewdech A, Cheung BMY, Tse G, Zhou J.
    Gastric Cancer; 2024 Sep 03; 27(5):947-970. PubMed ID: 38856768
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
    Lee S, Zhou J, Leung KSK, Wai AKC, Jeevaratnam K, King E, Liu T, Wong WT, Chang C, Wong ICK, Cheung BMY, Tse G, Zhang Q.
    Cardiovasc Drugs Ther; 2023 Jun 03; 37(3):561-569. PubMed ID: 35142921
    [Abstract] [Full Text] [Related]

  • 5. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study.
    Gao X, Zhang N, Lu L, Gao T, Chou OHI, Wong WT, Chang C, Wai AKC, Lip GYH, Zhang Q, Tse G, Liu T, Zhou J.
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb 23; 10(2):103-117. PubMed ID: 37962962
    [Abstract] [Full Text] [Related]

  • 6. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.
    Mui JV, Li L, Chou OHI, Azfar N, Lee A, Hui J, Lee S, Tse G, Zhou J.
    Acta Diabetol; 2023 Jul 23; 60(7):917-927. PubMed ID: 37000300
    [Abstract] [Full Text] [Related]

  • 7. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users.
    Zhou J, Lee S, Leung KSK, Wai AKC, Liu T, Liu Y, Chang D, Wong WT, Wong ICK, Cheung BMY, Zhang Q, Tse G.
    ESC Heart Fail; 2022 Apr 23; 9(2):1388-1399. PubMed ID: 35132823
    [Abstract] [Full Text] [Related]

  • 8. Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study.
    Chung CT, Lakhani I, Chou OHI, Lee TTL, Dee EC, Ng K, Wong WT, Liu T, Lee S, Zhang Q, Cheung BMY, Tse G, Zhou J.
    Cancer Med; 2023 Jun 23; 12(11):12299-12315. PubMed ID: 37148547
    [Abstract] [Full Text] [Related]

  • 9. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW, Chan CC, Chen SW, Kao YW, Huang CY, Chan YH, Chu PH.
    Cardiovasc Diabetol; 2020 Nov 06; 19(1):188. PubMed ID: 33158436
    [Abstract] [Full Text] [Related]

  • 10. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor.
    Lee HF, Chen SW, Liu JR, Li PR, Wu LS, Chang SH, Yeh YH, Kuo CT, Chan YH, See LC.
    Cardiovasc Diabetol; 2020 Sep 30; 19(1):160. PubMed ID: 32998736
    [Abstract] [Full Text] [Related]

  • 11. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH, Chao TF, Chen SW, Lee HF, Li PR, Chen WM, Yeh YH, Kuo CT, See LC, Lip GYH.
    Cardiovasc Diabetol; 2022 Jun 28; 21(1):118. PubMed ID: 35765074
    [Abstract] [Full Text] [Related]

  • 12. SGLT2i reduces risk of developing HCC in patients with co-existing type 2 diabetes and hepatitis B infection: A territory-wide cohort study in Hong Kong.
    Lee CH, Mak LY, Tang EH, Lui DT, Mak JH, Li L, Wu T, Chan WL, Yuen MF, Lam KS, Wong CKH.
    Hepatology; 2023 Nov 01; 78(5):1569-1580. PubMed ID: 37055020
    [Abstract] [Full Text] [Related]

  • 13. Comparison of incident hypertension between SGLT2 inhibitors vs. DPP4 inhibitors.
    Suzuki Y, Kaneko H, Okada A, Komuro J, Fujiu K, Takeda N, Morita H, Ako J, Nishiyama A, Yano Y, Ieda M, Node K, Yasunaga H, Komuro I.
    Hypertens Res; 2024 Jul 01; 47(7):1789-1796. PubMed ID: 38600275
    [Abstract] [Full Text] [Related]

  • 14. Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    Kawaguchi T, Fujishima Y, Wakasugi D, Io F, Sato Y, Uchida S, Kitajima Y.
    J Gastroenterol; 2024 Dec 01; 59(12):1120-1132. PubMed ID: 39392481
    [Abstract] [Full Text] [Related]

  • 15. Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study.
    Chou OHI, Lu L, Chung CT, Chan JSK, Chan RNC, Lee AYH, Dee EC, Ng K, Pui HHH, Lee S, Cheung BMY, Tse G, Zhou J.
    Diabetes Metab; 2024 Aug 23; 51(1):101571. PubMed ID: 39182669
    [Abstract] [Full Text] [Related]

  • 16. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM, Tan KCB, Lam DCL, Cheung BMY, Wong ICK, Kwok WC, Sing CW, Cheung CL.
    JAMA Netw Open; 2023 Jan 03; 6(1):e2251177. PubMed ID: 36648944
    [Abstract] [Full Text] [Related]

  • 17. Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
    Kashiwagi A, Shoji S, Kosakai Y, Koga T, Asakawa K, Rokuda M.
    J Diabetes Investig; 2023 Mar 03; 14(3):404-416. PubMed ID: 36515129
    [Abstract] [Full Text] [Related]

  • 18. The Effect of Sodium Glucose Cotransporter-2 Inhibitors on Hemoglobin A1c Variability and Acute Kidney Injury: A Causal Mediation Analysis.
    Wang T, Ji D, Stürmer T, Ismail S, Dong S, Shen P, Lin H, Shi L, Guan X, Xu Y.
    Pharmacoepidemiol Drug Saf; 2024 Aug 03; 33(8):e5876. PubMed ID: 39090775
    [Abstract] [Full Text] [Related]

  • 19. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV, Zhou J, Lee S, Leung KSK, Lee TTL, Chou OHI, Tsang SL, Wai AKC, Liu T, Wong WT, Chang C, Tse G, Zhang Q.
    Front Cardiovasc Med; 2021 Aug 03; 8():747620. PubMed ID: 34746262
    [Abstract] [Full Text] [Related]

  • 20. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M, Takayama A, Takeuchi M, Kawakami K.
    Diabetes Obes Metab; 2024 Aug 03; 26(8):3099-3109. PubMed ID: 38708591
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.